Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLJEFH)

Drug Name

Relacatib Drug Info

Synonyms

GSK-462795; SB-462795; Azepan-3-one compound 10; Relacatib (USAN/INN); N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Bone metastases	2D50	Discontinued in Phase 2	[1]
Osteoporosis	FB83.0	Discontinued in Phase 1	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[2]

Cross-matching ID

PubChem CID: 6918602
CAS Number: CAS 362505-84-8
TTD Drug ID: DMLJEFH

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cathepsin K (CTSK)	TTDZN01	CATK_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Cathepsin K (CTSK)	DTT	CTSK	7.502	8.157	6.955	8.046

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Bone metastases

ICD Disease Classification

2D50

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cathepsin K (CTSK)	DTT	CTSK	6.91E-04	1.59	1.81

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7862).
2	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.
3	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8.